Mammary Cell News Volume 9.27 | Jul 13 2017

TOP STORY

Cross Talk between Progesterone Receptors and Retinoic Acid Receptors in Regulation of Cytokeratin 5-Positive Breast Cancer Cells

The authors investigated the mechanisms by which progesterone receptors and retinoic acid receptors regulate cytokeratin 5 expression and breast cancer stem cell activity. [Oncogene] Abstract

(Ranked by impact factor of the journal)

LABORATORY RESEARCH

The EGFR/miR-338-3p/EYA2 Axis Controls Breast Tumor Growth and Lung Metastasis

Researchers showed that epidermal growth factor receptor (EGFR) promotes breast tumor growth and metastasis by downregulating the tumor suppressor miR-338-3p and activating the EYA transcriptional coactivator and phosphatase 2 (EYA2) oncoprotein. [Cell Death Dis] Full Article

An Autocrine Inflammatory Forward-Feedback Loop after Chemotherapy Withdrawal Facilitates the Repopulation of Drug-Resistant Breast Cancer Cells

Investigators revealed a new mechanism by which cytokines produced by breast cancer cells after chemotherapy withdrawal activate both Wnt/β-catenin and NF-κB pathways, which in turn further promote breast cancer cells to produce and secrete cytokines, forming an autocrine inflammatory forward-feedback loop to facilitate the enrichment of drug-resistant breast cancer cells and/or cancer stem-like cells. [Cell Death Dis] Full Article

Anti-Cancerous Effect of Albumin Coated Silver Nanoparticles on MDA-MB 231 Human Breast Cancer Cell Line

Albumin coated silver nanoparticles were synthesized, and their anti-cancerous effects were evaluated against MDA-MB 231, a human breast cancer cell line. [Sci Rep] Full Article

SRGN-TGFβ2 Regulatory Loop Confers Invasion and Metastasis in Triple-Negative Breast Cancer

Scientists investigated serglycin (SRGN) gene expression and how it regulates transforming growth factor-β2 (TGFβ2) and the downstream signaling of TGFβ2 in triple-negative breast cancer (TNBC) cells and tissues. They showed that SRGN mRNA and protein expression levels were significantly higher in TNBC cell lines and tumor tissues than that in non-TNBC cells and tissues. [Oncogenesis] Full Article

CXCR4 Targeted Dendrimer for Anti-Cancer Drug Delivery and Breast Cancer Cell Migration Inhibition

The efficacy of CXCR4 targeted dendrimers carrying DOX on cellular binding, cytotoxicity, and migration of BT-549-Luc and T47D breast cancer cells was investigated. [Eur J Pharm Biopharm] Abstract | Graphical Abstract

ω-Hydroxyundec-9-enoic Acid Induces Apoptosis by ROS Mediated JNK and p38 Phosphorylation in Breast Cancer Cell Lines

Scientists investigated the anti- breast cancer activity of ω-hydroxyundec-9-enoic acid (HUA) and its underlying mechanism. Treatment of human breast cancer cell lines, MDA-MB-231 and MDA-MB-435, with ω-HUA induced apoptotic cell death with increased cleaved caspase-3 and poly (ADP-ribose) polymerase levels, and p38 and JNK phosphorylation. [J Cell Biochem] Abstract

PRMT2β, a C-Terminal Splice Variant of PRMT2, Inhibits the Growth of Breast Cancer Cells

Researchers determined the role of arginine N-methyltransferase 2 (PRMT2β) in breast cancer cell proliferation, apoptosis and its effect on the Akt signaling pathway. Stable breast cancer MCF7 cell line with lentivirus-mediated PRMT2β overexpression was obtained after selection by puromycin for two weeks. [Oncol Rep] Abstract

Human SnoRNA-93 Is Processed into a MicroRNA-Like RNA that Promotes Breast Cancer Cell Invasion

Researchers performed an RNA-seq-based comparison of the small nucleolar RNA-derived RNAs of two breast cancer cell lines and identified small nucleolar RNA-derived RNAs derived from 13 small nucleolar RNAs overexpressed in MDA-MB-231 cells. [npj Breast Cancer] Full Article

CLINICAL RESEARCH

A Randomized Phase II Trial of Ridaforolimus, Dalotuzumab, and Exemestane Compared with Ridaforolimus and Exemestane in Patients with Advanced Breast Cancer

The authors evaluated whether adding humanized monoclonal insulin growth factor-1 receptor antibody to mammalian target of rapamycin inhibitor plus aromatase inhibitor improves outcomes in patients with estrogen receptor-positive advanced/metastatic breast cancer. [Breast Cancer Res Treat] Abstract

Possible Roles for Glucocorticoid Signaling in Breast Cancer

The authors summarize the current evidence for glucocorticoids as actors in breast cancer and then suggest future essential approaches in order to determine the roles of glucocorticoids in this disease. [Mol Cell Endocrinol] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Puma Biotechnology Completes Targeted Enrollment in Neratinib Phase III Metastatic Breast Cancer Trial

Puma Biotechnology, Inc. announced that targeted patient enrollment in the Phase III NALA trial of the company’s lead drug candidate PB272 in patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of HER2-directed treatments in the setting of metastatic disease has been completed. [Puma Biotechnology, Inc.] Press Release

CRISPR Therapeutics and Neon Therapeutics Enter Research Collaboration

CRISPR Therapeutics and Neon Therapeutics announced a research collaboration to explore the combination of each company’s proprietary technologies to develop novel T cell therapies. [CRISPR Therapeutics] Press Release

US Lawmakers Seek $1.1 Billion Boost for the NIH

The US National Institutes of Health (NIH) would see its budget rise by US$1.1 billion in 2018, to $35.2 billion, under a spending proposal released by lawmakers in the House of Representatives. [Nature News] Editorial

Marketing of Unproven Stem Cell–Based Interventions: A Call to Action

Commercial promotion of unsupported therapeutic uses of stem cells is a global problem that has proven resistant to regulatory efforts. The authors suggest a coordinated approach at the national and international levels focused on engagement, harmonization, and enforcement to reduce the risks associated with direct-to-consumer marketing of unproven stem cell treatments. [Sci Transl Med] Abstract | Editorial

In a Rare Move, FDA Reverses Course on Drug Developed by CEO with Ties to Trump

The Food and Drug Administration has changed its tune on an experimental drug for a deadly rare disease, withdrawing a request that the company developing it run another clinical trial. The unusual move comes after President Trump met with the company’s CEO — and promised to speed up what he called a “slow and burdensome” process for drug approvals. [STAT news] Editorial

NEW 3^rd World Congress on Controversies in Breast Cancer (CoBrCa)
October 26-28, 2017
Tokyo, Japan

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Fellow – Cancer Research (University of Texas Health Science Center at San Antonio)

Postdoctoral Positions – Molecular Cancer Research (University of Copenhagen and Rigshospitalet)

Postdoctoral Fellow – Cancer Genomics (University of Texas Health Science Center at Houston)

Canada Research Chair – Tumor Biology (University of Manitoba)

Postdoctoral Research Position – Experimental Oncology (KTH Royal Institute of Technology)

Postdoctoral Positions – Breast Cancer (Northwestern University – Feinberg School of Medicine)

Postdoctoral Training Fellow – Cancer Metabolism (The Francis Crick Institute)

Research Assistant – Breast Cancer (University of British Columbia)

Clinician Investigator – Breast Cancer Research (Mayo Clinic)

Postdoctoral Research Associate – Breast Cancer (University of Nebraska Medical Center)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.